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Management of esophageal variceal bleeding continues t~ be a 
difficult problem for the practicing physician. TIPS IS an 
interventional radiologic procedure that involves creating a 
channel within the liver between the portal vein and the systemic 
circulation using an expandable metallic stent. Ten patients 
underwent TIPS at St Francis Medical Center and the technical 
success rate was 100%. Complications have been minimal. One 
patient has died from progressive hepatic failure and carci-
noma, and 1 patientunderwentlivertransplantation. The remain-
ing 8 patients have a patent TIPS in place and have not rebled. 
Introduction 
Ideal management of acute variceal bleeding in the 1990s 
requires a closely coordinated effort between the primary care 
physician, gastroenterologist/hepatologist, surgeon, and 
interventional radiologist. All patients with suspected acute 
variceal bleeding should be managed in the intensive care unit 
with adequately trained nursing personnel. The latter play a 
critical but often unappreciated role in the minute-to-minute 
patient management. The goals of this team effort are to achieve 
hemodynamic stability, to prevent and treat complicatio.ns, and 
to control bleeding. All 3 goals must be addressed simulta-
neously and within hours of the patient's admission. 
Major causes of early mortality from these bleeding episo?es 
include aspiration pneumonia, renal failure (from hypovoleffila), 
encephalopathy, sepsis and multi-organ ~ysten: failure .. T~ese 
complications can be managed by aggressive flUid resuscitatiOn, 
correction of coagulation defects, lactulose, gut bacterial decon-
tamination with broad-spectrum, non-absorbable antibiotics, 
and nutritional support. 
There have been many modalities used to control bleeding, 
such as vasopressin/somatostatin infusion, balloon tamponade, 
endoscopic sclerotherapy (EST), endoscopic band ligation, sur-
gical portosystemic shunts, and esophageal transection. _In re-
cent years, EST has emerged as the treatment of choice to 
achieve hemostasis acutely and prophylactically. Notwithstand-
ing all efforts, end-stage liver disease still has a dismal 5-year 
survival rate. The natural history of variceal bleeding is such that 
50% to 60% of all bleeding will stop no matter what therapy is 
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used. 1 About 20% to 30% of variceal hemorrhages will be 
massive and may result in death.1-3 Furthermore, less than 40% 
of these patients will be alive one year after their first variceal 
bleed. 1.4 The ultimate treatment, and the only one that also will 
eliminate the underlying liver disease, is liver transplantation; 
the scarcity of donors, however, limits its widespread use. 
We now add TIPS to our list of treatment alternatives. TIPS 
is an interventional radiologic procedure that creates an artificial 
shunt through the liver parenchyma from the portal vein to the 
systemic circulation with the use of an expandable m~tal stent. 5 
It is essentially a side-to-side portocaval shunt without the 
morbidity and mortality of a surgical procedure. 
Methods and Materials 
This study is a retrospective review of the early cases of 
trans jugular intrahepatic portosystemic shunts performed at St 
Francis Medical Center. Patients were referred from throughout 
Hawaii and Guam for assistance in management of esophageal 
variceal bleeding. 
All patients underwent extensive evaluation with laboratory 
data to include assessment of renal function, liver function, 
coagulation parameters, and ammonia level. Esophago-
gastroduodenoscopy had been performed on all patients either at 
St Francis or by referring gastroenterologists to confirm the 
presence of esophagogastric varices. All patients underwent 
abdominal ultrasound with Doppler to assess patency of the 
hepatic and portal venous systems and the status of the _liver. 
Prior to TIPS, all patients received intravenous hydration and 
prophylactic antibiotics with cefoxitin. TIPS was performed in 
the special procedures room of the radiology department, and an 
anesthesiologist was present to monitor the patient and provide 
intravenous sedation. 
The technique as described by Dr Ernest Ring atthe University 
of California at San Francisco was used. 6 A jugular vein punc-
ture was performed and a catheter and guide wire were advanced 
through the superior vena cava. An initial pre-TIPS inferior vena 
cava pressure was obtained. The right or middle hepatic vein was 
then catheterized, and a 16-gauge Colapinto needle was passed 
from the hepatic vein into the right or left portal vein. A guide 
wire and catheter then were advanced into the main portal vein, 
a pre-TIPS portal vein pressure was obtained, and the pre-TIPS 
portal vein-IVC gradient was calculated. A portal venogram was 
performed to confirm correct placement and to assess anatomy 
and visualize esophageal varices. The parenchymal tract be-
tween the hepatic and portal veins was dilated with an angioplasty 
balloon. A metallic stentthen was placed in the tract, a post-TIPS 
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portal vein-IVC gradient was obtained and a portal venogram 
was repeated to assess the shunt. Esophageal varices were 
embolized with stainless steel coils if significant flow in the 
varices persisted after stent placement. 
Patients were observed post-TIPS for procedural complica-
tions, evidence of encephalopathy, progressive liver failure, or 
recurrence of bleeding. Following TIPS, abdominal ultrasound 
with Doppler was performed every 3 months for the first year to 
assess velocity across the TIPS and direction of flow within the 
portal vein. 
Results 
Ten patients underwent transjugularintrahepatic portosystemic 
shunt at St Francis Medical Center during the 11-month period 
between March 15, 1993 to February 15, 1994. Of these 3 
women and 7 men, the mean age was 48.4 years (range 38 to 73 
years). The etiology of liver failure included alcoholic cirrhosis 
in 6 patients, and 1 patient for each of the following: Cryptogenic 
cirrhosis, hepatitis C, hepatitis Blhepatoma, and hepatitis C/ 
alcoholic cirrhosis. All 10 patients had esophageal variceal 
bleeding, and 1 patient also had severe ascites which was 
refractory to medical management. These patients had 2 to 4 
episodes of variceal bleeding, and 6 patients had multiple 
sclerotherapy sessions. Six patients were actively bleeding 
within 1 week prior to TIPS, and 1 patient was bleeding in the 24 
hours prior to the procedure. 
TIPS was performed by a single interventional radiologist 
(LL) and the technical success rate was 100%.There was tech-
nical difficulty in 1 patient who required 2 sessions to complete 
the TIPS. In this particular case, the portal vein could not be 
located; a portal venogram via a superior mesenteric artery 
injection was performed to identify the course of the portal vein, 
and the TIPS was then successfully performed. The mean portal 
vein-inferior vena cava gradient was 21.9 mm Hg pre-TIPS and 
10.3 mm Hg post-TIPS. All procedures were accomplished 
under local anesthesia with intravenous sedation. The mean 
procedure length was 2.7 hours (range 1.3 to 4.0 hours). 
All patients remained in the intensive care unit or the post-
anesthesia recovery room for a 24-hour period following TIPS. 
The mean hospital stay following TIPS was 4 days (3 to 5 days). 
The only procedural complication was a pneumothorax, which 
was successfully managed with tube thoracostomy. 
Patients have been followed for 12 months post-TIPS. One 
patient died as a result of progressive liver failure and hepatocel-
lular carcinoma 2 months following TIPS. One patient under-
went a successful liver transplant 228 days following TIPS. The 
shunt was noted to be patent in his explanted liver. Of the 8 
remaining cases, 1 patient developed a stenosis of the draining 
hepatic vein at 2 months. This was manifested by recurrent 
ascites and hydrothorax which had been initially controlled with 
the TIPS. The stenosis was successfully restented, and this 
patient currently is doing well. In this series of patients, the 
primary shunt patency rate is 90% and the secondary patency 
rate is 100%. One patient demonstrated clinical evidence of 
encephalopathy, which was controlled with lactulose. This 
patient had mild encephalopathy prior to TIPS. The mean 
ammonia pre-TIPS was 39.7 fll110l/L and in the peri-procedure 
period this increased to a mean of 81.4 fll110l!L. Three patients 
are currently on lactulose for an elevated ammonia, but none of 
these patients has clinical symptoms of encephalopathy. One 
patient had a significant rise in AST from 37 lUlL to 1104 IU/ 
-
L (this patient suffered no consequences and his AST has since 
returned to normal), otherwise there was no significant change 
in bilirubin, AST, protime, or alkaline phosphatase in any of the 
remaining patients during the immediate post-procedure period. 
No patient has had recurrence of variceal hemorrhage. 
Discussion 
The first human intrahepatic portosystemic shunts were done 
in the early 1980s by Colapinto et al, who created a tract in the 
liver using a balloon catheter. These channels generally oc-
cluded within 30 days because of the elasticity of the liver 
parenchyma.7 The first successful TIPS in a human was per-
formed in Germany in 1988 by Richter et al using an expandable 
metallic stent devised by Palmaz.8 Since this first shunt, the 
procedure has been widely accepted in both the academic and 
community settings. 
There is a growing.body of data now available in the literature 
reporting efficacy and short-term follow-up.6•9-14 The largest 
published series are by LaBerge et al6 and Roessle et al, u both 
with 100 patients. Although randomized, double-blind studies 
comparing TIPS with other forms of therapy are not available, 
some reproducible results have been reported and preliminary 
conclusions can be drawn. 
TIPS has been performed on patients with cirrhosis of all 
etiologies, the most common being Laennec's cirrhosis. Patients 
of all Child's classes have been included. Liver function tests are 
usually abnormal. Patients aged 5 years to 84 years have been 
treated, with men treated more frequently than women.6•9-14 
The most common indication has been recurrent bleeding 
esophageal varices, refractory to endoscopic sclerotherapy. 
Additional indications include acute variceal bleeding not re-
sponsive to sclerotherapy or due to gastric or ectopic varices, and 
ascites refractory to medical therapy. 6•9·ll,l3·15 
Early studies reported technical success rates of75%,16-17 but 
more recently, because of the refinement of the technique, this 
has improved to 90% to 100%.6•10· 11•14·15,18-zo 
TIPS has been shown to be effective in controlling variceal 
bleeding in 86% to 100% of cases and in decreasing ascites in 
70% to 100% of cases.6•9-15 After creation of the shunt, portal 
blood flow has been shown by Doppler sonography to increase 
by 250%.u A reduction of the portal-systemic gradient by 50% 
to 75% usually is achieved 9•11•15 Portal venography performed 
during the procedure usually shows immediate decompression 
of esophageal varices. 6 Endoscopy performed within a month of 
the procedure has confirmed resolution of the varices in almost 
all cases.21 
Improvement of the ascites occurs rapidly over the days 
following the procedure; increased renal blood flow results in 
increased urine volume, improved creatinine clearance, and 
natriuresis.22 These findings also explain improved renal func-
tion in some TIPS patients with renal insufficiency.23 
The incidence of complications directly related to the proce-
dure is less than 5%; these include complications of placing a 
central venous catheter (pneumothorax, hemothorax, neck 
hematoma), fever, stent migration, bleeding (hemoperitoneum, 
liver hematoma, hemobilia), hepatic artery injury, bile duct 
injury, renal failure, and respiratory failure. 6·u·24 
Long-term complications seen with portacaval shunts also can 
be seen with TIPS, since TIPS is essentially a side-to-side 
portacaval shunt without an incision. Progressive liver failure 
can occur because blood flow is diverted from the hepatocytes. 
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LaBerge et al6 had a 9% mortality from progressive liver 
failure because a large number of their patients had severe 
(Child's C) cirrhosis. On the other hand, Roessle et al, who had 
fewer Child's C patients, had no deaths from progressive liver 
failure. 11 Both authors describe asymptomatic transient eleva-
tions in liver functions in some of their patients. 
Progressive liver failure also can be manifested as new onset 
or worsening of hepatic encephalopathy. This has been a major 
problem with surgical portacaval shunts.25 The incidence in 
TIPS patients appears to be 15% to 30%. The encephalopathy is 
usually not severe and is usually well-controlled with 
lactulose. 5•6•20•26-29 
Long-term shunt patency poses a major question. The best 
available data is 3 year follow-up by LaBerge et al (80% primary 
patency and 100% secondary patency) and Roessle et al (67% 
primary patency and 100% secondary patency). 11•30 Other inves-
tigators with shorter follow-up of 12 to 18 months have reported 
primary patency of 17% to 82% and secondary patency of 83% 
to 97%.12-13 Thus, the best estimate at this time, based on the 
above data, is that up to 33% of these shunts will fail in 3 years. 
These authors also have shown, however, that failed shunts 
due to stenosis or occlusion usually can be reopened through a 
transjugular approach, resulting in secondary patency rates 
approaching 100%. In order to detect shunt stenosis before shunt 
failure and rebleeding occurs, Doppler sonography now is being 
used. 32-33 A strategy of close surveillance and early reintervention 
may be the answer to long-term patency. 
Current research is also focusing on the biochemical and 
cellular processes that control the response of blood elements 
and the vessel wall to the metallic stent. Stents coated with 
heparin and other materials are being studied in experimental 
models.34 
The results of TIPS in the first patients at our center have been 
encouraging and are comparable to those reported in the litera-
ture. So far, we have achieved 100% technical success and have 
had no recurrent bleeding. One shunt stenosis, manifested by 
recurrent ascites, was successfully restented and complications 
have been few. Long-term patency rates and changes in hepatic 
synthetic function will need to be observed closely. Like other 
centers, a number of our patients will undergo liver transplanta-
tion. In these patients, TIPS will have served as a valuable bridge 
to transplantation, preventing life-threatening variceal hemor-
Fig 1.--contrast radiograph showing TIPS catheter (single arrowhead) running 
from hepatic to portal vein, a percutaneous catheter (double arrowhead) within the 
portal vein, and esophageal varices (triple arrowheads). 
rhage before an appropriate donor organ becomes available. 
Summary 
The management of bleeding esophageal varices continues to 
be one of the greatest challenges for the practicing physician. 
Recent advances in endoscopic techniques, pharmacologic in-
tervention, surgical decompression procedures and liver trans-
plantation have resulted in a more hopeful outlook for patients 
with this problem. TIPS has now been added to the list of 
possible therapies. Despite impressive short-term results, more 
data, including controlled clinical trials comparing TIPS with 
standard treatment options, are needed to determine relative 
long-term patency, efficacy, and overall survival. Notwith-
standing, TIPS has become widely used in the treatment of 
bleeding esophageal varices because of its relative 
noninvasiveness, safety, and excellent short-term results. Its 
future, although uncertain, is promising. 
Acknowledgements 
We would like to thank the following physicians for their patient referrals for 
TIPS: Drs Ronald Pang, Howard Minami, Ronald Ahloy, Joseph Hew, James 
Grobe, and Darrell Lee. 
References 
1. Graham DY, Smijh JL. The course of patients after variceal hemorrhage. Gastroenterology. 
1981 ;80:800-809. 
2. Smijh JL, Graham DY. Variceal hemorrhage: A critical evaluation of survival analysis. Gastroen· 
terology. 1982;82:968·973. 
3. Grace NO. A hepatologist view of variceal bleeding. Am J Surg. 1992;160:26-31. 
4. Nachlas MM, O'Neil JE, Campbell AJA. The life history of patients with cirrhosis of the 6ver and 
bleeding esophageal varices. Ann Surg. 1955;141 :1Q-23. 
5. Conn HO. Transjugular intrahepatic portal-systemic shunts: The state of the art. Hepatology. 
1993;17:148·157. 
6. LaBerge JM, Ring EJ, Gordon RL, Lake JR, Doherty MM, Samberg KA, Roberts JP, Ascher NL. 
T ransjugular intrahepatic portosystemic shunts (TIPS) wijh the walls tent endoprosthesis: ResuHs 
in 100 patients. Radiology. 1993;187:413-420. 
7. Colapinto RF, Stronell RD, Gikliner M, Mchie AC, Lange B, Taylor BR, Blendis LM. Fomnation 
of an intrahepatic portosystemic shunt using balloon dilatation catheter: Pre6minary clinical 
experience. Am J Roentgenology. 1983;140:709-714. 
8. Richter GM, Palmaz JC, Noeldge G. Der transjugulare intrahepatische portosystemische slant-
shunt (TIPSS). Radiologe. 1989;24:406-411. 
9. Zemel G, Katzen BT, BeckerGJ, BenenatiJF, Sallee S. Percutaneoustransjugularportosysternic 
shunt. JAMA 1991 ;266:39Q-393. 
10. Vinel JP, Rousseau H, Bilbao JL, Maquin P, Longo JM, Garcia L, Contreras F, Prieto J, Pascal 
JP, Joffre F. Transjugular intrahepatic portacaval shunts using the wallstent endoprosthesis: 
Prospective study in 66 patients. Hepato/ogy. 1992;16{suppl): 85A. Abstract. 
11. Roessle M, Haag K, Ochs A, Sellinger M, Nodge G, Peramau J, Berger E, Blum U, Gabelman 
A, Hauenstein K, Langer M, Gerok W. The transjugular intrahepatic portosystemic stent-shunt 
Ftg 2.-Radiograph showing contrast flowing through newly created shunt running 
from portal to hepatic vein. 
-
HAWAII MEDICAL JOURNAL VOL. 54, JANUARY 1995 
384 
procedure for variceal bleeding. N Eng/ J Med. 1994;330:165-171. 
12. Picus D, Darcy M, Vesely T, Hicks M, Dick l. Mayhle M. Efficacy and complications of trans jugular 
intrahepatic portD-systemic shunts. Presented at the RSNA 79th Scientific Assembly and Annual 
Meeting. 1993. 
13. Rosch J, Saxon R, Barton R, Petersen B, Lakin P, Keller F. T ransjugular intrahepatic portosystemic 
shunt: Middle-tenn shunt patency. Presented at the RSNA 79th Scientilic Assembly and Annual 
Meeting. 1993. 
14. Simpson KJ, Chalmers N, Redhead ON, Finlayson NDC, Bouchier AD, Hayes PC. Transjugular 
intrahepatic portasystemic stent shunting for control of acute and recurrent upper gastrointestinal 
haemorrhage related to portal hypertension. Gut. 1993;34:968·973. 
15. Freedman AM, Sanyal AJ, TISnado J, Shiffman ML. Luketic VA, FISher RA, Posner MP. Results 
with percutaneous transjugular intrahepatic portosystemic stent·shunts for control of variceal 
hemorrtlage in patients awaiting liver transplantation. Trans Proc. 1993;25:1087·1089. 
16. Roessle M, Noldge G, Richter GM, Haag K, Weizsacker FV, Wenz W, Gerok G, Palmaz JC. The 
transjugular intrahepatic portosystemic shunt (TIPSS): A l·year follow-up. Gastroenterology. 
1990;98:A625. Abstract. 
17. GordonJD, Colapinto RF, Abecassis M, MakowkaL, Langer B. Blendis LM, Taylor B, Stronell RD. 
T ransjugular intrahepatic portosystemic shunt: A nonoperative approach to l~e-threatening 
variceal bleeding. Canacian J Surg. 1987;30:45-49. 
18. HeHon WS, Belshaw A, AHhaus S, Park S, Coldwell D, Johansen K. Critical appraisal of 
angiographic portacaval shunt (TIPS). Am J Surg. 1993;165: 566-571. 
19. Ring EJ, Lake JR, Roberts JP, Gordon RL, LaBerge JM, Read AE, Stemeck MR, Ascher NL. 
Using transjugular intrahepatic portosystemic shunts to control variceal bleeding before liver 
transplantation. Ann lnt Med. 1992;116:304-309. 
20. LaBerge JM, Ring EJ, Lake JR, Ferrel LD, Doherty MM, Gordon RL. Roberts JP, Peltzer MY, 
Ascher NL. Transjugular intrahepatic portosystemic shunts: Preliminary results in 25 patients. J 
Vase Surg. 1992;16:258·267. 
21. Sanyal A, Freedman A, Luketic V, Purdum P, Shiffman M, DeMeo J. Transjugular intrahepatic 
portD-systemic shunt (TIPS) and pathophysiology of portal hypertension (PH): endoscopic, 
radiologic and biochemical correlations. Am J Gastroent.l992; 87:1305. Abstract. 
22. Sanyal A. Freedman A, Shiffman M, Purdum P, Luketic V. Transjugular intrahepatic porto· 
systemic shunts for ascites: a preliminary report. Am J Gastroent. 1992;87:1305. Abstract. 
23. LakeJR, Ring E. LaBergeJ, GordonR, RobertsJ,AscherN. Transjugularintrahepaticportacaval 
stent shunts in patients with renal insufficiency. Trans Proc. 1993;25:1766·1767. 
24. Hauenstein K, Haag K. Ochs A, Sellinger M, Langer M, Roessle M. Transjugular intrahepatic 
portosystemic shunts: Technical and early clinical complications. Presented at the RSNA 79th 
Scientific Assembly and Annual Meeting. 1993. 
25. Sanyal A. Purdum P, Luketic V, Shiffman M. Bleeding gastroesophageal varices. Sem Uvar 
Disease. 1993;13:328·342. 
26. Semnger M, Haag K, Ochs G, Noeldge G, Gerok W, Roessle M. Factors influencing the incidence 
of hepatic encephalopathy in patients with transjugular intrahepatic portosystemic stent·shunt (TIPS). Hepato/ogy. 1992;16(suppi):122A. Abstract. 
27. Somberg KA, Riegler JL, Donherty M, LaBerge JM, Bachetti P, Roberts JP, Lake JR. Hepatic 
encephalopathy following transjugular intrahepatic portosystemic shunts (TIPS): Incidence and 
risk factors. Hepato/ogy. 1992;16 (suppi):122A. Abstract. 
28. SanyaiAJ, Freedman AM. Transjugularintrahepaticportosystemicshunt (TIPS): practical issues 
of concern to a gastroenterologist. Am J Gastroent. 1992; 87:1305. 
29. Sanyal AJ, Freedman AM, Shiffman ML, Luketic VA. Purdum PP. PortosystemicencephaJopathy 
following transjugular intrahepatic portosystemic shunt: A controlled study. Hepato/ogy. 1992;16: 
85A. 
30. LaBerge J, RingE, Gordon R. Stenosis and occlusion of transjugular intrahepatic portasystemic 
shunts. Presented at the RSNA 79th Scient~ Assembly and Annual Meeting. t993. 
31. MaJisch T, Mazer M, Meranze S, Feuer I, Und C, Chong W. Ufe-table analysis of middle·tenn 
patency of transjugular intrahepatic portosystemic stent. Presented at the RSNA 79th Scientilic 
Assembly and Annual Meeting. 1993. 
32. Longo J, Bilbao J, Rousseau H, Garcia· Villareal L, Vinel J, Zozaya J, Joffre F, Prieto J. 
T ransjugular intrahepatic portosystemic shunt: Evaluation with Doppler sonography. Radiology. 
1993;186:529-534. 
33. Nazarian G, Ferral H, Hunter D, Castaneda-Zuniga W, Rengel G, Hennan M. Correlation of 
velocity of flow and residual portosystemic gradient with the early development of transjugular 
intrahepalic portosystemic shunt stenosis. Presented at the RSNA 79th Scient~ Assembly and 
Annual Meeting. 1993. 
34. Palmaz J, Sprague E. Hubbell J, Grabowski E, Minisymposium on Biomaterial Research. 
Presented at the SCVIR 19th Annual Scientific Meeting, 1994. 
-
Ftg 4.-Same stent expanded as it is used. 
Fig 5.-TIPS. Entering hepatic vein, catheterize the portal vein by traveling through 
liver parenchyma {B). Guidewire is shown in C; subsequent dilation of tract with 
balloon {0). Stant is placed and further dilated if necessary {E). After removing 
catheters, a newly created portal systemic shunt {F). 
Fig 6.-0blique cut through excised liver from patient 2 {liver transplantation) 
showing patent shunt running through liver parenchyma. {Courtesy Department of 
Pathology, St Francis Medical Center.) 
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